English

Taysha Gene Therapies, Inc.

EDGAR

TSHA Quarterly report (10-Q) · filed 2026-08-11

Annual consolidated revenue for 2025: about USD 9.773M, using the latest reported figures. The previous period, 2024, was about USD 8.333M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-40.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -81303000 USD Source
Operating Cash Flow: -40878000 USD Source

Cash and cash equivalents: 455 million USD 2026-06-30 Source
Exact value

455400000 USD
Long-term debt including current maturities: 38.4 million USD 2023-06-30 Source
Exact value

38354000 USD
Shares outstanding: 325 million shares 2026-06-30 Source
Exact value

325302280 shares

Reported share-count change

19.28% · 52.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

272730060 shares · 2025-06-30· Source
325302280 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

5.49 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 0 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 9773000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 4288000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-150 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -32733000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -108995000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -81144000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -42410000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -46639000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-132 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -66368000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -42202000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -93090000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -66368000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -40878000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -81303000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -40878000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

384 thousand USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Capital expenditure: 380000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 378000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 488000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 380000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 738000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 488000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 24000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-11.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 4 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 4 of 11 periods available· newest 2025-12-31
Current liabilities: 4 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2022-12-31
Shares outstanding: 4 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+17.3%

Prior period

USD 8.33 million

2024-01-01 – 2024-12-31
Current period

USD 9.77 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

9773000 − 8333000 = 1440000 USD

8333000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
9773000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Year-over-year change in Revenue: 1440000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 9773000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#3256218 Filing: 000119312526115202 Input fundies:Revenue: 8333000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#3257843 Filing: 000119312526115202
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 19.7 million

Prior period

−USD 89.3 million

2024-01-01 – 2024-12-31
Current period

−USD 109 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-108995000 − -89298000 = -19697000 USD

-89298000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-108995000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Year-over-year change in Net income: -19697000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -108995000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1792092 Filing: 000119312526115202 Input fundies:NetIncome: -89298000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1683789 Filing: 000119312526115202
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 11.87 million

Prior period

−USD 81.23 million

2024-01-01 – 2024-12-31
Current period

−USD 93.09 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-93090000 − -81225000 = -11865000 USD

-81225000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-93090000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Year-over-year change in Operating cash flow: -11865000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -93090000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1874186 Filing: 000119312526115202 Input fundies:OperatingCashFlow: -81225000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1876041 Filing: 000119312526115202
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+97.3%

Prior period

USD 374,000

2024-01-01 – 2024-12-31
Current period

USD 738,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

738000 − 374000 = 364000 USD

374000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
738000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Year-over-year change in Capital expenditure: 364000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 738000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1880832 Filing: 000119312526115202 Input fundies:CapitalExpenditure: 374000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1882571 Filing: 000119312526115202
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 9.77 million 100% of revenue
Operating costs Derived USD 120.27 million 1,231% of revenue
Operating income −USD 110.5 million −1,131% of revenue
Tax, interest and other Derived −USD 1.5 million −15% of revenue
Net income −USD 109 million −1,115% of revenue

Cash

Operating cash flow −USD 93.09 million −953% of revenue
Capital expenditure USD 738,000 7.6% of revenue
Free cash flow Derived −USD 93.83 million −960% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Operating loss: operating costs were 6,593% of revenue.
2023 Operating loss: operating costs were 569% of revenue.
2024 Operating loss: operating costs were 1,198% of revenue.
2025 Operating loss: operating costs were 1,231% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	2502000	164949000 Derived	-162447000	3567000 Derived	-166014000	-109009000 Derived	Source 2022-01-01 – 2022-12-31: 2502000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -162447000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -166014000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -88390000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 20619000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	15451000	87890000 Derived	-72439000	39127000 Derived	-111566000	-76887000 Derived	Source 2023-01-01 – 2023-12-31: 15451000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -72439000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -111566000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -73018000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 3869000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	8333000	99792000 Derived	-91459000	-2161000 Derived	-89298000	-81599000 Derived	Source 2024-01-01 – 2024-12-31: 8333000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -91459000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -89298000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -81225000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 374000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	9773000	120271000 Derived	-110498000	-1503000 Derived	-108995000	-93828000 Derived	Source 2025-01-01 – 2025-12-31: 9773000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -110498000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -108995000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -93090000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 738000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 9.8M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	2502000	Revenue: 2502000 Open source
20232023-12-31	Revenue	15451000	Revenue: 15451000 Open source
20242024-12-31	Revenue	8333000	Revenue: 8333000 Open source
20252025-12-31	Revenue	9773000	Revenue: 9773000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

17.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 2502000 Open source
20232023-12-31	Year over year	517.5%	Revenue: 15451000 Open source Revenue: 2502000 Open source
20242024-12-31	Year over year	-46.1%	Revenue: 8333000 Open source Revenue: 15451000 Open source
20252025-12-31	Year over year	17.3%	Revenue: 9773000 Open source Revenue: 8333000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,130.6% 2025

Net margin -1,115.3% 2025

Free cash flow margin -960.1% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	-6,492.7%	Operating Income: -162447000 Open source Revenue: 2502000 Open source
20232023-12-31	Operating margin	-468.8%	Operating Income: -72439000 Open source Revenue: 15451000 Open source
20242024-12-31	Operating margin	-1,097.6%	Operating Income: -91459000 Open source Revenue: 8333000 Open source
20252025-12-31	Operating margin	-1,130.6%	Operating Income: -110498000 Open source Revenue: 9773000 Open source
20222022-12-31	Net margin	-6,635.3%	Net Income: -166014000 Open source Revenue: 2502000 Open source
20232023-12-31	Net margin	-722.1%	Net Income: -111566000 Open source Revenue: 15451000 Open source
20242024-12-31	Net margin	-1,071.6%	Net Income: -89298000 Open source Revenue: 8333000 Open source
20252025-12-31	Net margin	-1,115.3%	Net Income: -108995000 Open source Revenue: 9773000 Open source
20222022-12-31	Free cash flow margin	-4,356.9%	Revenue: 2502000 Open source Operating Cash Flow: -88390000 Open source Capital Expenditure: 20619000 Open source
20232023-12-31	Free cash flow margin	-497.6%	Revenue: 15451000 Open source Operating Cash Flow: -73018000 Open source Capital Expenditure: 3869000 Open source
20242024-12-31	Free cash flow margin	-979.2%	Revenue: 8333000 Open source Operating Cash Flow: -81225000 Open source Capital Expenditure: 374000 Open source
20252025-12-31	Free cash flow margin	-960.1%	Revenue: 9773000 Open source Operating Cash Flow: -93090000 Open source Capital Expenditure: 738000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -93.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-88390000	Operating Cash Flow: -88390000 Open source
20232023-12-31	Operating cash flow	-73018000	Operating Cash Flow: -73018000 Open source
20242024-12-31	Operating cash flow	-81225000	Operating Cash Flow: -81225000 Open source
20252025-12-31	Operating cash flow	-93090000	Operating Cash Flow: -93090000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -93.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-109009000	Operating Cash Flow: -88390000 Open source Capital Expenditure: 20619000 Open source
20232023-12-31	Free cash flow	-76887000	Operating Cash Flow: -73018000 Open source Capital Expenditure: 3869000 Open source
20242024-12-31	Free cash flow	-81599000	Operating Cash Flow: -81225000 Open source Capital Expenditure: 374000 Open source
20252025-12-31	Free cash flow	-93828000	Operating Cash Flow: -93090000 Open source Capital Expenditure: 738000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.1% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Liabilities / assets	99.2%	Total Liabilities: 125327000 Open source Total Assets: 126276000 Open source
20232023-12-31	Liabilities / assets	56.6%	Total Liabilities: 97794000 Open source Total Assets: 172731000 Open source
20242024-12-31	Liabilities / assets	55.4%	Total Liabilities: 88839000 Open source Total Assets: 160364000 Open source
20252025-12-31	Liabilities / assets	28.1%	Total Liabilities: 96382000 Open source Total Assets: 343320000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

12.23× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Current assets / current liabilities	1.54×	Current Assets: 96417000 Open source Current Liabilities: 62790000 Open source
20232023-12-31	Current assets / current liabilities	4.08×	Current Assets: 149868000 Open source Current Liabilities: 36756000 Open source
20242024-12-31	Current assets / current liabilities	5.42×	Current Assets: 142130000 Open source Current Liabilities: 26227000 Open source
20252025-12-31	Current assets / current liabilities	12.23×	Current Assets: 324647000 Open source Current Liabilities: 26552000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 60.01 million Exact value Exact value: -60011000 USD 2020-01-01 – 2020-12-31: -60011000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Taysha Gene Therapies, Inc. · 2020-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Net Income: -60011000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60011000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000156459022012782/tsha-10k_20211231.htm#1780287 Filing: 000156459022012782 The citation records this snapshot. The page link may show a newer release later.	−USD 30.73 million Exact value Exact value: -30729000 USD 2020-01-01 – 2020-12-31: -30729000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Taysha Gene Therapies, Inc. · 2020-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Operating Cash Flow: -30729000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -30729000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000156459022012782/tsha-10k_20211231.htm#1921351 Filing: 000156459022012782 The citation records this snapshot. The page link may show a newer release later.	USD 82,000 Exact value Exact value: 82000 USD 2020-01-01 – 2020-12-31: 82000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Taysha Gene Therapies, Inc. · 2020-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Capital Expenditure: 82000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 82000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000156459022012782/tsha-10k_20211231.htm#1933219 Filing: 000156459022012782 The citation records this snapshot. The page link may show a newer release later.	−USD 30.81 million Calculation and evidence -30729000 − 82000 USD Exact free cash flow: -30811000 USD 2020-01-01 – 2020-12-31: -30729000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 82000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Taysha Gene Therapies, Inc. · 2020-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Free cash flow: -30811000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -30729000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000156459022012782/tsha-10k_20211231.htm#1921351 Filing: 000156459022012782 Input fundies:CapitalExpenditure: 82000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000156459022012782/tsha-10k_20211231.htm#1933219 Filing: 000156459022012782 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 174.52 million Exact value Exact value: -174523000 USD 2021-01-01 – 2021-12-31: -174523000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Taysha Gene Therapies, Inc. · 2021-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Net Income: -174523000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -174523000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017023010343/tsha-20221231.htm#1694555 Filing: 000095017023010343 The citation records this snapshot. The page link may show a newer release later.	−USD 117.04 million Exact value Exact value: -117042000 USD 2021-01-01 – 2021-12-31: -117042000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Taysha Gene Therapies, Inc. · 2021-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Operating Cash Flow: -117042000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117042000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017023010343/tsha-20221231.htm#1870018 Filing: 000095017023010343 The citation records this snapshot. The page link may show a newer release later.	USD 15.3 million Exact value Exact value: 15304000 USD 2021-01-01 – 2021-12-31: 15304000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Taysha Gene Therapies, Inc. · 2021-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Capital Expenditure: 15304000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15304000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017023010343/tsha-20221231.htm#1882884 Filing: 000095017023010343 The citation records this snapshot. The page link may show a newer release later.	−USD 132.35 million Calculation and evidence -117042000 − 15304000 USD Exact free cash flow: -132346000 USD 2021-01-01 – 2021-12-31: -117042000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 15304000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Taysha Gene Therapies, Inc. · 2021-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Free cash flow: -132346000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117042000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017023010343/tsha-20221231.htm#1870018 Filing: 000095017023010343 Input fundies:CapitalExpenditure: 15304000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017023010343/tsha-20221231.htm#1882884 Filing: 000095017023010343 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 166.01 million Exact value Exact value: -166014000 USD 2022-01-01 – 2022-12-31: -166014000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Taysha Gene Therapies, Inc. · 2022-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Net Income: -166014000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -166014000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017024033484/tsha-20231231.htm#1498528 Filing: 000095017024033484 The citation records this snapshot. The page link may show a newer release later.	−USD 88.39 million Exact value Exact value: -88390000 USD 2022-01-01 – 2022-12-31: -88390000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Taysha Gene Therapies, Inc. · 2022-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Operating Cash Flow: -88390000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -88390000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017024033484/tsha-20231231.htm#1607026 Filing: 000095017024033484 The citation records this snapshot. The page link may show a newer release later.	USD 20.62 million Exact value Exact value: 20619000 USD 2022-01-01 – 2022-12-31: 20619000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Taysha Gene Therapies, Inc. · 2022-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Capital Expenditure: 20619000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 20619000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017024033484/tsha-20231231.htm#1614786 Filing: 000095017024033484 The citation records this snapshot. The page link may show a newer release later.	−USD 109.01 million Calculation and evidence -88390000 − 20619000 USD Exact free cash flow: -109009000 USD 2022-01-01 – 2022-12-31: -88390000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 20619000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Taysha Gene Therapies, Inc. · 2022-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Free cash flow: -109009000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -88390000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017024033484/tsha-20231231.htm#1607026 Filing: 000095017024033484 Input fundies:CapitalExpenditure: 20619000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017024033484/tsha-20231231.htm#1614786 Filing: 000095017024033484 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 111.57 million Exact value Exact value: -111566000 USD 2023-01-01 – 2023-12-31: -111566000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Taysha Gene Therapies, Inc. · 2023-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Net Income: -111566000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -111566000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017025027348/tsha-20241231.htm#1645498 Filing: 000095017025027348 The citation records this snapshot. The page link may show a newer release later.	−USD 73.02 million Exact value Exact value: -73018000 USD 2023-01-01 – 2023-12-31: -73018000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Taysha Gene Therapies, Inc. · 2023-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Operating Cash Flow: -73018000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -73018000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017025027348/tsha-20241231.htm#1803784 Filing: 000095017025027348 The citation records this snapshot. The page link may show a newer release later.	USD 3.87 million Exact value Exact value: 3869000 USD 2023-01-01 – 2023-12-31: 3869000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Taysha Gene Therapies, Inc. · 2023-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Capital Expenditure: 3869000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3869000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017025027348/tsha-20241231.htm#1813172 Filing: 000095017025027348 The citation records this snapshot. The page link may show a newer release later.	−USD 76.89 million Calculation and evidence -73018000 − 3869000 USD Exact free cash flow: -76887000 USD 2023-01-01 – 2023-12-31: -73018000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3869000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Taysha Gene Therapies, Inc. · 2023-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Free cash flow: -76887000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -73018000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017025027348/tsha-20241231.htm#1803784 Filing: 000095017025027348 Input fundies:CapitalExpenditure: 3869000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000095017025027348/tsha-20241231.htm#1813172 Filing: 000095017025027348 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 89.3 million Exact value Exact value: -89298000 USD 2024-01-01 – 2024-12-31: -89298000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Taysha Gene Therapies, Inc. · 2024-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Net Income: -89298000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89298000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1683789 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.	−USD 81.23 million Exact value Exact value: -81225000 USD 2024-01-01 – 2024-12-31: -81225000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Taysha Gene Therapies, Inc. · 2024-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Operating Cash Flow: -81225000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -81225000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1876041 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.	USD 374,000 Exact value Exact value: 374000 USD 2024-01-01 – 2024-12-31: 374000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Taysha Gene Therapies, Inc. · 2024-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Capital Expenditure: 374000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 374000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1882571 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.	−USD 81.6 million Calculation and evidence -81225000 − 374000 USD Exact free cash flow: -81599000 USD 2024-01-01 – 2024-12-31: -81225000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 374000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Taysha Gene Therapies, Inc. · 2024-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Free cash flow: -81599000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -81225000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1876041 Filing: 000119312526115202 Input fundies:CapitalExpenditure: 374000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1882571 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 109 million Exact value Exact value: -108995000 USD 2025-01-01 – 2025-12-31: -108995000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Net Income: -108995000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -108995000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1792092 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.	−USD 93.09 million Exact value Exact value: -93090000 USD 2025-01-01 – 2025-12-31: -93090000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Operating Cash Flow: -93090000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93090000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1874186 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.	USD 738,000 Exact value Exact value: 738000 USD 2025-01-01 – 2025-12-31: 738000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Capital Expenditure: 738000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 738000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1880832 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.	−USD 93.83 million Calculation and evidence -93090000 − 738000 USD Exact free cash flow: -93828000 USD 2025-01-01 – 2025-12-31: -93090000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 738000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Taysha Gene Therapies, Inc. · 2025-12-31 Taysha Gene Therapies, Inc. (edgar:1806310) Free cash flow: -93828000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:50:49Z Snapshot: c961b534e39a33705b23a2846e6a6397185e64ad19daf0b0d0bc23a5ff6e74b5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1806310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93090000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1874186 Filing: 000119312526115202 Input fundies:CapitalExpenditure: 738000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm#1880832 Filing: 000119312526115202 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

30 filings · 1,513 latest values · 1,513 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001806310, 1806310, TSHA, edgar:1806310

Also known as Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation